Thursday, August 25, 2016 5:21:47 PM
What I do know is that the FDA has not improved the Copaxone landscape one iota with the approval of Glatopia. The FDA hasn't created a competitive landscape as desired. Actually, prices increased this year.
The reason for Generic's isn't too spread the wealth around, it's too create competition. A 3rd and 4th player will be needed and that's not lost on the FDA.
I wouldn't be surprised if someone else would be approved along with Momenta's 40mg.
We'll see.
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • BLOZF • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
